CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.362
EU - Europa 7.484
AS - Asia 6.790
SA - Sud America 1.107
Continente sconosciuto - Info sul continente non disponibili 301
AF - Africa 282
OC - Oceania 34
AN - Antartide 1
Totale 26.361
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.855
RU - Federazione Russa 3.418
SG - Singapore 2.480
CN - Cina 1.859
IT - Italia 1.072
BR - Brasile 819
GB - Regno Unito 816
VN - Vietnam 713
HK - Hong Kong 585
FR - Francia 444
DE - Germania 439
BD - Bangladesh 406
IE - Irlanda 361
SE - Svezia 266
CA - Canada 222
FI - Finlandia 190
KR - Corea 188
UA - Ucraina 137
IN - India 120
AR - Argentina 104
NL - Olanda 73
ID - Indonesia 63
MX - Messico 62
NG - Nigeria 61
EC - Ecuador 59
CO - Colombia 50
JP - Giappone 50
TR - Turchia 45
ZA - Sudafrica 45
AT - Austria 44
BJ - Benin 44
PL - Polonia 42
IQ - Iraq 41
CR - Costa Rica 37
ES - Italia 34
AU - Australia 31
PK - Pakistan 30
SV - El Salvador 30
HN - Honduras 29
PH - Filippine 25
SA - Arabia Saudita 25
TN - Tunisia 25
NI - Nicaragua 23
CL - Cile 21
IL - Israele 21
LT - Lituania 21
TT - Trinidad e Tobago 20
BE - Belgio 19
VE - Venezuela 19
MA - Marocco 18
MY - Malesia 18
CW - ???statistics.table.value.countryCode.CW??? 17
JM - Giamaica 17
UZ - Uzbekistan 17
EG - Egitto 16
GR - Grecia 15
GT - Guatemala 15
PR - Porto Rico 15
PT - Portogallo 15
TG - Togo 15
KE - Kenya 14
TH - Thailandia 14
PY - Paraguay 13
NP - Nepal 12
CH - Svizzera 11
DK - Danimarca 11
PE - Perù 11
AE - Emirati Arabi Uniti 10
SC - Seychelles 10
DO - Repubblica Dominicana 8
BB - Barbados 7
KZ - Kazakistan 7
OM - Oman 7
AL - Albania 6
BO - Bolivia 6
CZ - Repubblica Ceca 6
EU - Europa 6
GP - Guadalupe 6
JO - Giordania 6
KG - Kirghizistan 6
RO - Romania 6
TW - Taiwan 6
DZ - Algeria 5
EE - Estonia 5
ET - Etiopia 5
HR - Croazia 5
IR - Iran 5
PS - Palestinian Territory 5
QA - Qatar 5
AO - Angola 4
AZ - Azerbaigian 4
BG - Bulgaria 4
HU - Ungheria 4
RS - Serbia 4
SY - Repubblica araba siriana 4
CI - Costa d'Avorio 3
CU - Cuba 3
GD - Grenada 3
KH - Cambogia 3
LB - Libano 3
Totale 26.024
Salva come PNG Salva come JPEG
Città #
Ashburn 1.560
Singapore 1.294
San Jose 1.258
Moscow 1.121
Dallas 978
Hong Kong 577
Southend 577
Jacksonville 563
Chandler 556
Council Bluffs 385
Beijing 362
Dublin 352
Verona 329
The Dalles 309
Ho Chi Minh City 232
New York 229
Los Angeles 186
Munich 165
Hanoi 164
Princeton 153
Lawrence 152
Wilmington 151
Jinan 129
Santa Clara 123
Woodbridge 114
Nanjing 110
Shenyang 110
Helsinki 108
Houston 101
Buffalo 96
São Paulo 91
Milan 83
Redondo Beach 82
Tianjin 75
Hebei 66
London 56
Rome 53
Chicago 49
Montreal 49
Toronto 48
Abuja 47
Orem 47
Zhengzhou 47
Cotonou 44
Frankfurt am Main 44
Sindelfingen 44
Tokyo 44
Phoenix 43
Brooklyn 41
Changsha 40
Columbus 40
Taizhou 39
Bologna 37
Guangzhou 37
Jiaxing 37
Ann Arbor 36
Dearborn 36
Haikou 35
Jakarta 34
Redmond 34
Seattle 34
Warsaw 34
Grafing 32
Hangzhou 32
Denver 31
Dong Ket 31
Ningbo 31
Haiphong 30
Atlanta 29
Nanchang 29
San Francisco 29
San José 28
San Salvador 28
Chennai 26
Guayaquil 26
Norwalk 26
Rio de Janeiro 26
Taiyuan 26
Turku 26
McKinney 24
Boston 23
Johannesburg 23
Manchester 23
Naples 23
Lanzhou 22
Washington 22
Belo Horizonte 21
Managua 21
Mexico City 21
Philadelphia 21
Amsterdam 20
Boardman 20
Nuremberg 20
Redwood City 20
Vienna 20
Baghdad 19
Fuzhou 19
North Bergen 19
Stockholm 19
Charlotte 18
Totale 14.994
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 408
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 305
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 253
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 250
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 237
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 227
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 212
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 202
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 201
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 196
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 191
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 189
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 189
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 188
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 187
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 186
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 185
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 182
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 180
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 179
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 178
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 176
A prognostic model for patients with lymphoma and {COVID}-19: a multicentre cohort study 175
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis 174
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 171
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 170
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 170
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 167
Genetic and phenotypic attributes of splenic marginal zone lymphoma 167
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 166
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 165
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis 165
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 164
Autoimmune cytopenias in chronic lymphocytic leukemia 164
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 163
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 162
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 161
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 161
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report 160
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 160
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 159
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 157
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 156
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 155
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 154
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 154
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 154
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 151
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 151
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 151
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 151
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 150
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 150
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 149
Bendamustine plus rituximab: is it a BRIGHT idea? 149
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 147
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 144
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 143
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 142
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 142
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 142
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 141
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 141
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 140
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 138
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 138
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 137
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 136
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 136
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 134
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and {CAR}-T Cell Therapy 134
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 133
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 133
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 131
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 131
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma 130
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 130
Computerized drug management in a Bone Marrow Transplant Unit: towards an improvement of hospital drug management 128
Aggressive B-cell Lymphoma with {MYC}/{TP}53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents 128
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network 127
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 126
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 126
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 124
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 124
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 124
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma 123
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 123
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 122
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium 122
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 121
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 121
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 120
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 119
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 119
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 118
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 117
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 116
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study 116
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 116
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 115
Totale 15.795
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.930
article - articoli 88.078
book - libri 0
conference - conferenze 7.852
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.860
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022598 0 0 0 0 32 27 44 64 34 29 58 310
2022/20231.964 166 167 208 260 184 519 31 113 211 18 49 38
2023/20241.067 38 91 81 102 98 211 50 105 12 32 173 74
2024/20253.515 203 188 86 566 131 141 176 213 500 271 309 731
2025/202613.104 734 883 807 1.700 3.333 800 1.054 747 1.249 711 515 571
2026/20273.074 366 462 611 1.612 23 0 0 0 0 0 0 0
Totale 26.361